Global Impact of Optimal Implementation of Guideline-Directed Medical Therapy in Heart Failure

医学 药物治疗 内科学 心力衰竭 射血分数 重症监护医学 急诊医学 梅德林 心脏病学 死亡率
作者
Amber Tang,Boback Ziaeian,Javed Butler,Clyde W. Yancy,Gregg C. Fonarow
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:9 (12): 1154-1154 被引量:11
标识
DOI:10.1001/jamacardio.2024.3023
摘要

Importance Guideline-directed medical therapy (GDMT) remains underutilized on a global level, with significant disparities in access to treatment worldwide. The potential global benefits of quadruple therapy on patients with heart failure with reduced ejection fraction (HFrEF) have not yet been estimated. Objective To assess the projected population-level benefit of optimal GDMT use globally among patients with HFrEF. Design, Setting, and Participants Estimates for HFrEF prevalence, contraindications to GDMT, treatment rates, and the number needed to treat for all-cause mortality at 12 months were derived from previously published sources. Potential lives saved from optimal implementation of quadruple therapy among patients with HFrEF was calculated globally and a sensitivity analysis was conducted to account for uncertainty in the existing data. Main Outcomes and Measures All-cause mortality. Results Of an estimated 28.89 million people with HFrEF worldwide, there were 8 235 063 (95% CI, 6 296 020-10 762 972) potentially eligible for but not receiving β-blockers, 20 387 000 (95% CI, 15 867 004-26 184 996) eligible for but not receiving angiotensin receptor–neprilysin inhibitors, 12 223 700 (95% CI, 9 376 895-15 924 973) eligible for but not receiving mineralocorticoid receptor antagonists, and 21 229 170 (95% CI, 16 537 400-27 242 688) eligible for but not receiving sodium glucose cotransporter-2 inhibitors. Optimal implementation of quadruple GDMT could potentially prevent 1 188 277 (95% CI, 767 933-1 914 561) deaths over 12 months. A large proportion of deaths averted were projected in Southeast Asia, Eastern Mediterranean and Africa, and the Western Pacific regions. Conclusions and Relevance Improvement in use of GDMT could result in substantial mortality benefits on a global scale. Significant heterogeneity also exists across regions, which warrants additional study with interventions tailored to country-level differences for optimization of GDMT worldwide.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小树苗完成签到 ,获得积分10
刚刚
萨尔莫斯完成签到,获得积分10
1秒前
拼搏太英完成签到,获得积分10
1秒前
zzz完成签到 ,获得积分10
2秒前
芋头读文献完成签到,获得积分10
3秒前
Sebastian完成签到,获得积分10
3秒前
穆仰完成签到,获得积分10
4秒前
青云完成签到,获得积分10
4秒前
FashionBoy应助v小飞侠101采纳,获得10
5秒前
5秒前
娇娇完成签到,获得积分10
5秒前
落霞与孤鹜齐飞完成签到,获得积分10
6秒前
葡萄小伊ovo完成签到 ,获得积分10
8秒前
Edward发布了新的文献求助10
8秒前
SciGPT应助Ray采纳,获得10
9秒前
青衣完成签到,获得积分10
10秒前
Zhuyin发布了新的文献求助10
10秒前
大猪完成签到 ,获得积分10
13秒前
jasmine完成签到,获得积分10
14秒前
踏实凝云完成签到,获得积分10
14秒前
嘉博学长完成签到,获得积分10
14秒前
跳跃完成签到,获得积分10
15秒前
Lexi完成签到 ,获得积分10
16秒前
沉静野狼完成签到,获得积分10
16秒前
希望天下0贩的0应助weiwei采纳,获得10
16秒前
标致咖啡发布了新的文献求助10
17秒前
博修完成签到,获得积分20
17秒前
陆aa完成签到 ,获得积分10
19秒前
dujinjun完成签到,获得积分10
19秒前
zm完成签到,获得积分10
20秒前
历史真相发布了新的文献求助10
22秒前
尤瑟夫完成签到 ,获得积分10
22秒前
Rookie完成签到 ,获得积分10
23秒前
xczhu完成签到,获得积分0
26秒前
ZYY完成签到,获得积分10
27秒前
calico完成签到,获得积分10
27秒前
smottom应助标致咖啡采纳,获得10
28秒前
凯旋侯完成签到,获得积分10
29秒前
李健的粉丝团团长应助hui采纳,获得10
30秒前
汪蔓蔓完成签到 ,获得积分10
30秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Kinesiophobia : a new view of chronic pain behavior 2000
Research for Social Workers 1000
Psychology and Work Today 800
Kinesiophobia : a new view of chronic pain behavior 600
Signals, Systems, and Signal Processing 510
Discrete-Time Signals and Systems 510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5894269
求助须知:如何正确求助?哪些是违规求助? 6695659
关于积分的说明 15725953
捐赠科研通 5016265
什么是DOI,文献DOI怎么找? 2701627
邀请新用户注册赠送积分活动 1647998
关于科研通互助平台的介绍 1597951